Blueprint Medicines

Blueprint Medicines is a rising player in the dynamic biotech scene of the Greater Zurich Area. Their dedication to developing innovative treatments for individuals with systemic mastocytosis, cancer, and other serious illnesses exemplifies the potential of precision medicine to target the root cause of a disease. Since its establishment in 2011 in Cambridge, Massachusetts, Blueprint Medicines has made remarkable progress, including the development of a focused pipeline and two drugs that are already marketed worldwide and are approved by SwissMedic.

Why did Blueprint Medicines choose the Greater Zurich Area?

In 2018, when Blueprint Medicines decided to expand to Europe, they set their sights on Zug. Our conversations with them revealed that their decision was driven by the strong biotech ecosystem in both Zug and Zurich. Not only did Zug offer a business-friendly environment, but its standing as a hub in the biotech sector and its central location in Europe cemented its appeal. Additionally, the proximity to Zurich, known for its rich talent pool, research facilities, and dynamic business environment, added further weight to their decision.

Georg Pirmin Meyer, Senior Vice President and General Manager of Blueprint Medicines International highlighted the importance of this decision, stating, “People living with oncologic or hematologic conditions corresponding to rare diseases like systemic mastocytosis face unprecedented challenges. At Blueprint Medicines, we have ambitious goals to overcome those challenges and know that no person or organization alone can achieve them. The Greater Zurich Area provides us with access to the talent, partnerships, and resources we need to deliver for the rare disease community and to transform breakthrough science into more time for life.” Blueprint Medicines has grown to a workforce of around 70 employees throughout Europe, emphasizing their commitment to job creation and their faith in the region's potential.

The Greater Zurich Area provides us with access to the talent, partnerships, and resources we need to deliver to the rare disease community.

Georg Pirmin Meyer - Senior Vice President and General Manager

The future of Blueprint Medicines in the Greater Zurich Area

Blueprint Medicines is well-positioned in the Greater Zurich Area with its scientific excellence, economic stability, and high quality of life. With over a decade of scientific leadership behind them, the company is keen on realizing the promise of precision medicine. The Greater Zurich Area Ltd. is proud to be part of this exciting journey and looks forward to continuing its support for Blueprint Medicines.